These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36674610)

  • 21. Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
    Park JY; Kim GH; Kim SS; Ko JM; Lee JJ; Yoo HW
    Exp Mol Med; 2009 Jan; 41(1):1-7. PubMed ID: 19287194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.
    Citro V; Cammisa M; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.
    Citro V; Peña-García J; den-Haan H; Pérez-Sánchez H; Del Prete R; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
    PLoS One; 2016; 11(10):e0165463. PubMed ID: 27788225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fabry Disease: The Current Treatment Landscape.
    Lenders M; Brand E
    Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
    Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
    Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
    Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
    Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease.
    Zhou C; Huang J; Cui G; Zeng H; Wang DW; Zhou Q
    BMC Med Genet; 2018 Dec; 19(1):219. PubMed ID: 30587147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.
    Shin SH; Kluepfel-Stahl S; Cooney AM; Kaneski CR; Quirk JM; Schiffmann R; Brady RO; Murray GJ
    Pharmacogenet Genomics; 2008 Sep; 18(9):773-80. PubMed ID: 18698230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
    Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
    J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developments in the treatment of Fabry disease.
    van der Veen SJ; Hollak CEM; van Kuilenburg ABP; Langeveld M
    J Inherit Metab Dis; 2020 Sep; 43(5):908-921. PubMed ID: 32083331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme enhancers for the treatment of Fabry and Pompe disease.
    Lukas J; Pockrandt AM; Seemann S; Sharif M; Runge F; Pohlers S; Zheng C; Gläser A; Beller M; Rolfs A; Giese AK
    Mol Ther; 2015 Mar; 23(3):456-64. PubMed ID: 25409744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives.
    Asano N; Ishii S; Kizu H; Ikeda K; Yasuda K; Kato A; Martin OR; Fan JQ
    Eur J Biochem; 2000 Jul; 267(13):4179-86. PubMed ID: 10866822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The molecular basis of pharmacological chaperoning in human α-galactosidase.
    Guce AI; Clark NE; Rogich JJ; Garman SC
    Chem Biol; 2011 Dec; 18(12):1521-6. PubMed ID: 22195554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of fabry disease: current and emerging strategies.
    Rozenfeld P; Neumann PM
    Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.
    Lukas J; Giese AK; Markoff A; Grittner U; Kolodny E; Mascher H; Lackner KJ; Meyer W; Wree P; Saviouk V; Rolfs A
    PLoS Genet; 2013; 9(8):e1003632. PubMed ID: 23935525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ.
    Ferri L; Malesci D; Fioravanti A; Bagordo G; Filippini A; Ficcadenti A; Manna R; Antuzzi D; Verrecchia E; Donati I; Mignani R; Cavicchi C; Guerrini R; Morrone A
    Clin Chim Acta; 2018 Jun; 481():25-33. PubMed ID: 29476735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla
    Elsaid HOA; Rivedal M; Skandalou E; Svarstad E; Tøndel C; Birkeland E; Eikrem Ø; Babickova J; Marti HP; Furriol J
    J Transl Med; 2023 Sep; 21(1):591. PubMed ID: 37670295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A thermodynamic assay to test pharmacological chaperones for Fabry disease.
    Andreotti G; Citro V; Correra A; Cubellis MV
    Biochim Biophys Acta; 2014 Mar; 1840(3):1214-24. PubMed ID: 24361605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
    Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.